AbCellera Biologics Inc.
NASDAQ:ABCLBiotechnology
-$0.02 today
- Market cap
- $3.60B
- Beta
- 1.20
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.47
Volume 2.58M
Average 6.37M
ABCL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
AbCellera Biologics Inc.NASDAQ: ABCL
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables turns negative
Q3 FY2026 accounts receivables was -$4.3M, compared with $4.16M a year earlier. Trailing-twelve-month accounts receivables was -$43.84M. Over 3 fiscal years it compounded at +34.8% a year.
Context
- Accounts receivables amounted to 74.0% of revenue in FY2025, down 186.5 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$4.3M or moves back toward the trailing-twelve-month quarterly average of -$10.96M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (55.62M) USD
- Year-over-year change
- +26.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (55.62M) | +26.0% |
| FY2024 | 2024-12-31 | (75.12M) | -63.5% |
| FY2023 | 2023-12-31 | (45.93M) | -102.2% |
| FY2022 | 2022-12-31 | (22.72M) | -201.1% |
| FY2021 | 2021-12-31 | 22.48M | — |
Accounts Receivables vs competitors
How ABCL compares with its peers on the latest reported figures
- ABCL's LTM Sep 2026 accounts receivables of $43.84M is the largest of the 4 companies compared; the peer median is $1.38M.
- Its year-over-year change of +19.1% is the lowest of 4, against a peer median of +212.5%.
- Accounts receivables amounts to 64.6% of revenue for ABCL, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $43.84M | +19.1% | +34.8% | 64.6% | |
| LTM Mar 2026 | $2.98M | +212.5% | — | 2.1% | |
| LTM Mar 2026 | $1.38M | +207.1% | — | 75.4% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $308K | +244.6% | — | 1.0% |
| Peer median (excluding ABCL) | $1.38M | +212.5% | — | 2.1% | |
Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 153.46M | 158.52M | (146.4M) | (162.86M) | (146.41M) |
| Depreciation & Amortization | 17.25M | 33.1M | 30.89M | 97M | 28.82M |
| Deferred Income Tax | (2.02M) | (2.11M) | 1.96M | 0 | 0 |
| Stock-Based Compensation | 30.65M | 49.48M | 64.18M | 67.58M | 55.79M |
| Change in Working Capital | 41.67M | 29.83M | 13.23M | (25.84M) | (70.69M) |
| Accounts Receivables | 22.48M | (22.72M) | (45.93M) | (75.12M) | (55.62M) |
| Inventory | 0 | 0 | 18.25M | 0 | 0 |
| Accounts Payables | 1.4M | 1.07M | (15.1M) | 10.64M | 3.46M |
| Other Working Capital | 17.79M | 51.47M | 56.01M | 38.64M | (18.53M) |
| Other Non-Cash Items | 3.57M | 8.55M | (7.74M) | (84.44M) | 1.2M |
| Operating Cash Flow | 244.58M | 277.36M | (43.88M) | (108.56M) | (131.3M) |
| Capital Expenditures | (58.45M) | (72.66M) | (77.51M) | (78.4M) | (42.77M) |
| Acquisitions (Net) | (11.46M) | (25.68M) | (13.69M) | (19.63M) | (7.14M) |
| Purchases of Investments | (322.57M) | (781.35M) | (1.07B) | (765.09M) | (453.14M) |
| Sales of Investments | 27.61M | 510.63M | 910.94M | 948.81M | 506.07M |
| Other Investing Activities | 32.62M | 16.43M | 25.31M | 35.71M | 84.72M |
| Investing Cash Flow | (332.25M) | (352.63M) | (221.11M) | 121.41M | 87.75M |
| Debt Repayment | (951K) | 2.76M | 11.59M | 13.5M | 0 |
| Common Stock Issued | 4.62M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.55M) | (4.38M) | (1.23M) | (729K) | 14.08M |
| Financing Cash Flow | (3.89M) | (1.63M) | 10.36M | 12.77M | 14.08M |
| Effect of Forex Changes | (1.43M) | (9.6M) | 589K | (2.62M) | 1.1M |
| Net Change in Cash | (92.97M) | (86.49M) | (254.04M) | 23.01M | (28.37M) |
| Free Cash Flow | 186.13M | 204.7M | (121.38M) | (186.95M) | (174.07M) |
AbCellera Biologics Inc.
NASDAQ:ABCL
Intrinsic Alpha fair value
Locked
Current Price
$11.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.